CarlJackFichtenbaumMD
Infectious Disease • Cincinnati, OHHIV/AIDS Medicine
Professor of Medicine, University Cincinnati
Dr. Fichtenbaum is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Albert Sabin Way
405
Cincinnati, OH 45267Phone+1 513-584-6977Fax+1 513-584-6040
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Infectious Disease, 1991 - 1994
Yale-New Haven Medical CenterFellowship, Infectious Disease, 1990 - 1991
Bridgeport Hospital/Yale UniversityResidency, Internal Medicine, 1985 - 1990
University of Missouri Kansas City School of MedicineClass of 1985
Certifications & Licensure
OH State Medical License 1999 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2012-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium
- DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) Start of enrollment: 2006 May 01
- HIV Screening in the Emergency Department Setting Start of enrollment: 2008 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 350 citationsEfficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.Hana M. El Sahly, Lindsey R. Baden, Brandon Essink, Susanne Doblecki-Lewis, Judith M. Martin
The New England Journal of Medicine. 2021-09-22 - 437 citationsGuidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of...Michael P. Dubé, James H. Stein, Judith A. Aberg, Carl J. Fichtenbaum, John G. Gerber
Clinical Infectious Diseases. 2003-09-01 - 31 citationsComparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial f...David A. Wohl, Gretchen S. Arnoczy, Carl J. Fichtenbaum, Thomas B. Campbell, Babafemi Taiwo
Antiviral Therapy. 2013-02-01
Journal Articles
- Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Grou...Steven G Deeks, James H Stein, Carl Fichtenbaum, Judith S Currier, Priscilla Y Hsue, Eric S Daar, Ahmed Tawakol, Michael Lederman, Tanvir Bell, Diane Havlir, Clinical Infectious Diseases
Press Mentions
What Does It Mean to Be Immunocompromised?October 10th, 2024- Here’s How the End of the COVID-19 Public Health Emergency Could Affect You, According to MDsFebruary 14th, 2023
- 'It's Happening a Little Bit Earlier.' Flu Hospitalizations Rise in Southwest OhioNovember 10th, 2022
- Join now to see all
Grant Support
- University Of Cincinnati AIDS Clinical Trials Unit- UC ActuNational Institute Of Allergy And Infectious Diseases2008–2012
- HIV Protease Inhibitors And Calcium Channel BlockersNational Center For Research Resources2004
- ACTG A5108 Efavirenz/Nelfinavir StudyNational Center For Research Resources2004
- Epidemiology And Outcome Of STDS In Drug UsersNational Institute On Drug Abuse1999
- Washu55--Orally Administered SP 303 Treatment Of Diarrhea Aids--37, 554National Center For Research Resources1999
- Epidemiology And Outcome Of STDS In Drug UsersNational Institute On Drug Abuse1996–1998
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
